MapLight Therapeutics (MPLT) Enterprise Value (2025 - 2026)
MapLight Therapeutics (MPLT) posted Enterprise Value of -$711.5 million for Q4 2025, down 213.19% sequentially from -$227.2 million in Q3 2025, and down 553.96% YoY from $156.7 million in Q4 2024.
Powered by 
Analysis
MapLight Therapeutics (MPLT) Enterprise Value (2025 - 2026) Analysis & Trends
MapLight Therapeutics has reported Enterprise Value for 2 years, with the latest figure at -$711.5 million in Q4 2025.
- Quarterly Enterprise Value fell 553.96% year-over-year to -$711.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$711.5 million (down 553.96% YoY) and the FY2025 annual result came in at -$711.5 million, down 553.96% from the prior year.
- Enterprise Value retreated to -$711.5 million in Q4 2025 per MPLT's latest filing, from -$227.2 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$108.8 million in Q4 2024 and troughed at -$711.5 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | MapLight Therapeutics | 636.95 Mn | 636.95 Mn | - |